Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avdoralimab for bullous pemphigoid
2020-002912-34Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avdoralimab in Bullous Pemphigoid (BP) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Complete clinical remission at 3 months without relapse. Started Jun 2020; status: completed.
02
Drugs
avdoralimab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2020-002912-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002912-34.